Who are Inozyme Pharma's investors?

Inozyme Pharma's investors include BioMarin Pharmaceutical, Pivotal bioVenture Partners, Sofinnova Investments, Longitude Capital, RA Capital Management, Cowen Healthcare Investments.

When was Inozyme Pharma founded?

Inozyme Pharma was founded in 2017.

Where is Inozyme Pharma headquartered?

Inozyme Pharma is headquartered in Cambridge, Massachusetts, United States.

What industry is Inozyme Pharma in?

Inozyme Pharma operates in biotechnology, rare diseases.

How many employees does Inozyme Pharma have?

Inozyme Pharma has 11-50 employees.

Inozyme Pharma

Acquired

Pioneering therapies for rare diseases of abnormal mineralization.

Cambridge, United States · Founded 2017

biotechnology

rare diseases

Headquarters: Cambridge, Massachusetts
Employees: 11–50
Founded: 2017
Business Model: B2B

Website: inozyme.com
Last Round: Series AApr 2019
Rounds: 2

About

Inozyme Pharma, founded in 2017 and headquartered in Boston, Massachusetts, was a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases characterized by abnormal mineralization. The company's lead program, INDEE, targeted ENPP1 deficiency, a life-threatening rare disease affecting the heart, vasculature, and skeleton. With approximately 50 employees, Inozyme went public on Nasdaq (INZY) before being acquired by BioMarin Pharmaceutical in May 2025 for $270 million.

Summary

Inozyme Pharma is a biotechnology company based in Cambridge, United States, founded in 2017. Its most recent funding was a Series A round in Apr 2019. Investors include BioMarin Pharmaceutical, Pivotal bioVenture Partners and Sofinnova Investments.